皮下植入式心律转复除颤器系统上市后研究
S-ICD PAS 是在 86 家美国中心开展的前瞻性多中心注册研究,纳入 1,643 例符合标准适应症的患者,中位随访 4.2 年。所有预设安全性和有效性终点均达成,室速/室颤放电有效率 98.4%,S-ICD 相关和电极相关无并发症率分别为 93.4% 和 99.3%。
要点
- S-ICD 放电有效率 98.4%,各随访年度间无显著差异(P = 0.68)。
- S-ICD 相关和电极相关无并发症率分别为 93.4% 和 99.3%。
- 仅 1.6% 患者因起搏需求更换为经静脉 ICD。
核心结论
- 在迄今最大规模的前瞻性 S-ICD 研究中,尽管队列合并症多于既往多数试验,所有研究终点均达成,并发症率低且放电有效率高。
研究设计与样本
- S-ICD PAS 是一项真实世界、多中心、美国中心注册研究,纳入 86 家美国中心符合标准 S-ICD 适应症的患者,前瞻性观察最长 5 年。
- 共纳入 1,643 例患者,中位随访 4.2 年,采用预设性能目标评估终点。
主要发现
- 离散室速或室颤事件的放电有效率率为 98.4%,各随访年度间无显著差异(P = 0.68)。
- S-ICD 相关无并发症率为 93.4%,电极相关无并发症率为 99.3%。
- 仅 1.6% 患者因起搏需求将装置更换为经静脉 ICD。
- 累积全因死亡率为 21.7%。
临床怎么用
- 对于符合标准 S-ICD 适应症的患者,S-ICD 可作为避免经静脉导线相关并发症的长期选择。
- 因起搏需求而需更换为经静脉 ICD 的比例较低,但仍需在术前评估起搏需求。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to avoid complications related to transvenous implantable cardioverter-defibrillator (TV-ICD) leads. Device safety and efficacy were demonstrated previously with atypical clinical patients or limited follow-up. OBJECTIVES: The S-ICD PAS (Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study) is a real-world, multicenter, registry of U.S. centers that was designed to assess long-term S-ICD safety and efficacy in a diverse group of patients and implantation centers. METHODS: Patients were enrolled in 86 U.S. centers with standard S-ICD indications and were observed for up to 5 years. Efficacy endpoints were first and final shock efficacy. Safety endpoints were complications directly related to the S-ICD system or implantation procedure. Endpoints were assessed using prespecified performance goals. RESULTS: A total of 1,643 patients were prospectively enrolled, with a median follow-up of 4.2 years. All prespecified safety and efficacy endpoint goals were met. Shock efficacy rates for discrete episodes of ventricular tachycardia or ventricular fibrillation were 98.4%, and they did not differ significantly across follow-up years (P = 0.68). S-ICD-related and electrode-related complication-free rates were 93.4% and 99.3%, respectively. Only 1.6% of patients had their devices replaced by a TV-ICD for a pacing need. Cumulative all-cause mortality was 21.7%. CONCLUSIONS: In the largest prospective study of the S-ICD to date, all study endpoints were met, despite a cohort with more comorbidities than in most previous trials. Complication rates were low and shock efficacy was high. These results demonstrate the 5-year S-ICD safety and efficacy for a large, diverse cohort of S-ICD recipients. (Subcutaneous Implantable Cardioverter-Defibrillator [S-ICD] System Post Approval Study [PAS]; NCT01736618).
引用
- Gold MR, El-Chami MF, Burke MC, et al. Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System. J Am Coll Cardiol. 2023. PMID: 37495274. doi:10.1016/j.jacc.2023.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。